Overview

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
Phase:
Phase 2
Details
Lead Sponsor:
University of Utah
Treatments:
Bortezomib
Hemostatics